Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

PROGRAM CO-CHAIRS

Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member

Dr. Johann Gudjonsson, MD, PhD is a graduate of the University of Iceland Medical School. He completed his internship and dermatology residency training at the University of Michigan. In 2008, Dr. Gudjonsson joined the faculty of the University of Michigan Department of Dermatology. Dr. Gudjonsson sees general dermatology patients at the University of Michigan Taubman Center and directs the inpatient consultation service.

Dr. Gudjonsson came to the U-M in 2003 as part of an innovative research residency training program. Building upon investigative dermatology training completed in Iceland, Dr. Gudjonsson has been performing basic immunological and genetic work on psoriasis at the U-M. Dr. Gudjonsson's primary research focus is basic immunological and genetic research on psoriasis, with projects directed at improving the diagnosis and treatment of psoriasis. Dr. Gudjonsson is the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. He received the Young Investigator Award from the American Academy of Dermatology in 2007 and his work has earned several research awards, including awards from the American Skin Association, the Dermatology Foundation, Doris Duke Foundation and the NIH.

Last Updated: Jan 08, 2020

Nicole L. Ward, PhD
Case Western Reserve University
Cleveland, Ohio, United States

Dr. Ward is an Associate Prof. of Dermatology and Director of the Morphology Core of the Skin Diseases Research Center in the Department of Dermatology at Case Western Reserve University and University Hospitals Case Medical Center. As a researcher, Dr. Ward has obtained national and international research funding. Her work has primarily focused on three unique, but overlapping, conceptual areas in psoriasis pathogenesis. They are: 1) skin inflammation drives remote vascular inflammation and thrombosis, 2) the neural activation of skin inflammation and proliferation, and 3) elucidating a role for Il-17c and IL-17RE signaling in psoriasis pathogenesis. Dr. Ward has been first or senior author on more than 50 publications and has been invited as a plenary speaker at national and international meetings.

Last Updated: Jan 26, 2018

PROGRAM FACULTY

Vinod Chandran, MBBS, MD, DM, PhD
University of Toronto
Toronto, Ontario, Canada

Vinod Chandran MBBS MD DM PhD, a Rheumatologist and clinician-scientist, is an Associate Professor of Medicine & Laboratory Medicine and Pathobiology at the University of Toronto, an Adjunct Professor at the Memorial University of Newfoundland, an affiliate scientist at the Krembil Research Institute, a member of the graduate faculty at the Institute of Medical Science, University of Toronto, a scientist with the Creative Destruction Lab, Rotman School of Management, University of Toronto and a staff physician at the University Health Network and Mount Sinai Hospitals. He co-directs the Psoriatic Disease Program at the University Health Network, Toronto, Canada.

Dr. Chandran’s research interests lie in the genetic and molecular epidemiology of psoriasis and psoriatic arthritis, especially with regard to prognosis. His translational research program is focused on developing proteomics and metabolomics-based screening and prognostic tools for psoriatic arthritis. His bench research aims to identify mechanisms underlying inflammation and joint damage in psoriatic arthritis, and developing novel topical and systemic anti- psoriatic therapies. He is also investigating the cutaneous microbiome in psoriasis and PsA and its relationship to psoriatic disease phenotype and genotype. He is a member of the executive committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He is an active collaborator in multi-centre research consortia such as the International Psoriasis and Arthritis Research Team and the Spondyloarthritis Research Consortium of Canada and aims to conduct validation studies of discoveries made at his program through these collaborations.

Last Updated: Mar 06, 2020


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK